<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0003613'>Antiphospholipid antibody</z:hpo> syndrome (APS) has been widely recognized to be associated with various neurological complications </plain></SENT>
<SENT sid="1" pm="."><plain>In addition to the classical notion of APS as a thrombotic disorder, APS has been suggested to be an autoinflammatory disease as well </plain></SENT>
<SENT sid="2" pm="."><plain>We present a previously healthy 46-year-old man who concurrently developed <z:e sem="disease" ids="C0026976" disease_type="Disease or Syndrome" abbrv="">transverse myelitis</z:e> and <z:e sem="disease" ids="C0085655" disease_type="Disease or Syndrome" abbrv="">polymyositis</z:e> whose laboratory studies were significant for the elevated <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> such as anti-<z:chebi fb="0" ids="28494">cardiolipin</z:chebi> (CL)/beta2-<z:chebi fb="2" ids="17089">glycoprotein</z:chebi> I (beta 2GPI) antibody </plain></SENT>
<SENT sid="3" pm="."><plain>This report further enhances the recognized clinical phenotypes of the neurological complications of APS and the understanding of its pathomechanism </plain></SENT>
</text></document>